- Home
- INMB vs JHI Comparison
INMB vs JHI Comparison
Compare INMB & JHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INMB | JHI |
|---|---|---|
| Founded | 2015 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.2M | 123.7M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | INMB | JHI |
|---|---|---|
| Price | $1.67 | $13.62 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | ★ 496.6K | 29.5K |
| Earning Date | 10-30-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.80% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.05 |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | $264.29 | N/A |
| Revenue Next Year | $14,337.26 | N/A |
| P/E Ratio | ★ N/A | $12.47 |
| Revenue Growth | ★ 19.05 | N/A |
| 52 Week Low | $1.38 | $11.63 |
| 52 Week High | $11.64 | $13.40 |
Technical Indicators
Market Signals| Indicator | INMB | JHI |
|---|---|---|
| Relative Strength Index (RSI) | 42.13 | 41.22 |
| Support Level | $1.75 | $13.42 |
| Resistance Level | $1.90 | $13.70 |
| Average True Range (ATR) | 0.14 | 0.10 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 3.72 | 22.08 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.